首页> 外文期刊>American Journal of Translational Research >The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2
【24h】

The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2

机译:Covid-19大流行和新型冠状病毒SARS-COV-2的潜在治疗

获取原文
           

摘要

Coronavirus SARS-CoV-2 is a novel coronavirus and the seventh that can infect human beings and result in severe and acute respiratory syndrome and deaths. Currently, the world is undergoing a global health emergency due to the SARS-CoV-2 pandemic. As of May 18, SARS-CoV-2 has spread to over two hundred countries and infected more than 4.8 million people, resulting in over 300,000 deaths since the first case of a novel pneumonia (COVID-19) patient was discovered in Wuhan, China at the end of December 2019. Currently, there are no effective and/or approved targeting drugs for it though various supportive therapy drugs such as small molecule drugs, vaccines, antibodies and even Chinese herb medicines have been used in the treatment of the first-line patients. However, certain drugs such as remdesivir and S416 are under clinical investigation and may become therapeutic drugs. In this article, we review and discuss SARS-CoV-2, its person-to-person transmission, genomics and proteomics, and the potential for drug development.
机译:冠状病毒SARS-COV-2是一种新型冠状病毒和第七次,可以感染人类,导致严重和急性呼吸综合征和死亡。目前,由于SARS-COV-2大流行,世界正在全球健康紧急情况。截至5月18日,SARS-COV-2已蔓延到超过两百个国家,感染了超过480万人,以来,自中国武汉发现了新的肺炎(Covid-19)患者的第一种案例以来,导致超过300,000人死亡截至2019年12月底。目前,虽然各种支持性治疗药物如小分子药物,疫苗,抗体甚至中国药草药物,但都没有有效和/或批准的靶向药物已用于治疗第一 - 线患者。然而,某些药物如雷级虫草和S416都在临床调查下进行,并且可能成为治疗药物。在本文中,我们审查并讨论SARS-COV-2,其人为的传播,基因组学和蛋白质组学,以及药物开发的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号